Literature DB >> 27248629

CDX2 as a Prognostic Biomarker in Colon Cancer.

Marta Schirripa1, Fotios Loupakis2, Heinz-Josef Lenz3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27248629      PMCID： PMC7521111          DOI： 10.1056/NEJMc1602584

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.

Authors:  Jung Ho Kim; Ye-Young Rhee; Jeong Mo Bae; Nam-Yun Cho; Gyeong Hoon Kang
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

2.  BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.

Authors:  Michael S Landau; Shih-Fan Kuan; Simon Chiosea; Reetesh K Pai
Journal:  Hum Pathol       Date:  2014-04-24       Impact factor: 3.466

3.  BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome.

Authors:  Z Saridaki; D Papadatos-Pastos; M Tzardi; D Mavroudis; E Bairaktari; H Arvanity; E Stathopoulos; V Georgoulias; J Souglakos
Journal:  Br J Cancer       Date:  2010-05-18       Impact factor: 7.640

4.  Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status.

Authors:  Alessandro Lugli; Alexandar Tzankov; Inti Zlobec; Luigi Maria Terracciano
Journal:  Mod Pathol       Date:  2008-06-27       Impact factor: 7.842

5.  Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.

Authors:  J Souglakos; J Philips; R Wang; S Marwah; M Silver; M Tzardi; J Silver; S Ogino; S Hooshmand; E Kwak; E Freed; J A Meyerhardt; Z Saridaki; V Georgoulias; D Finkelstein; C S Fuchs; M H Kulke; R A Shivdasani
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640
  5 in total
  2 in total

1.  CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer.

Authors:  Fotios Loupakis; Paola Biason; Alessandra Anna Prete; Chiara Cremolini; Filippo Pietrantonio; Nicoletta Pella; Emanuela Dell'Aquila; Elisa Sperti; Clizia Zichi; Rossana Intini; Vincenzo Dadduzio; Marta Schirripa; Francesca Bergamo; Carlotta Antoniotti; Federica Morano; Francesco Cortiula; Giovanna De Maglio; Lorenza Rimassa; Valeria Smiroldo; Lorenzo Calvetti; Giuseppe Aprile; Lisa Salvatore; Daniele Santini; Giada Munari; Roberta Salmaso; Vincenza Guzzardo; Claudia Mescoli; Sara Lonardi; Massimo Rugge; Vittorina Zagonel; Massimo Di Maio; Matteo Fassan
Journal:  Br J Cancer       Date:  2019-09-02       Impact factor: 7.640

2.  Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.

Authors:  Sara Ribeirinho-Soares; Diana Pádua; Ana Luísa Amaral; Elvia Valentini; Daniela Azevedo; Cristiana Marques; Rita Barros; Filipa Macedo; Patrícia Mesquita; Raquel Almeida
Journal:  BMC Cancer       Date:  2021-04-06       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.